Novakand Pharma AB (publ) (LARK) - Total Liabilities

Latest as of December 2025: Skr1.24 Million SEK ≈ $133.34K USD

Based on the latest financial reports, Novakand Pharma AB (publ) (LARK) has total liabilities worth Skr1.24 Million SEK (≈ $133.34K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see Novakand Pharma AB (publ) asset portfolio.

Novakand Pharma AB (publ) - Total Liabilities Trend (2012–2025)

This chart illustrates how Novakand Pharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See Novakand Pharma AB (publ) (LARK) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Novakand Pharma AB (publ) Competitors by Total Liabilities

The table below lists competitors of Novakand Pharma AB (publ) ranked by their total liabilities.

Company	Country	Total Liabilities
Ta Win Holdings Bhd KLSE:7097	Malaysia	RM165.56 Million
Carmell Therapeutics Corporation NASDAQ:CTCX	USA	$7.14 Million
Co-Diagnostics, Inc. Common Stock NASDAQ:CODX	USA	$5.46 Million
Enthusiast Gaming Holdings Inc TO:EGLX	Canada	CA$63.28 Million
Fancy Wood Industries Public Company Limited BK:FANCY	Thailand	฿33.48 Million
Dunedin Income Growth Investment Trust PLC LSE:DIG	UK	GBX50.01 Million
DSS Inc NYSE MKT:DSS	USA	$66.02 Million
Golden Tobacco Limited NSE:GOLDENTOBC	India	Rs2.05 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Novakand Pharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check Novakand Pharma AB (publ) liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.37	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.02	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.02	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novakand Pharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novakand Pharma AB (publ) (2012–2025)

The table below shows the annual total liabilities of Novakand Pharma AB (publ) from 2012 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr1.24 Million ≈ $133.34K	-71.19%
2024-12-31	Skr4.30 Million ≈ $462.75K	+3.47%
2023-12-31	Skr4.16 Million ≈ $447.22K	-31.86%
2022-12-31	Skr6.10 Million ≈ $656.32K	-23.21%
2021-12-31	Skr7.94 Million ≈ $854.68K	-0.49%
2020-12-31	Skr7.98 Million ≈ $858.87K	-66.06%
2019-12-31	Skr23.51 Million ≈ $2.53 Million	+60.38%
2018-12-31	Skr14.66 Million ≈ $1.58 Million	+801.06%
2017-12-31	Skr1.63 Million ≈ $175.10K	+100.96%
2016-12-31	Skr809.66K ≈ $87.13K	+17.05%
2015-12-31	Skr691.73K ≈ $74.44K	+18.85%
2014-12-31	Skr582.04K ≈ $62.64K	+1320.21%
2013-12-31	Skr40.98K ≈ $4.41K	-86.18%
2012-12-31	Skr296.58K ≈ $31.92K	--

About Novakand Pharma AB (publ)

ST:LARK USA Asset Management

Market Cap

$4.60 Million

Skr42.77 Million SEK

Market Cap Rank

#28827 Global

#5877 in USA

Share Price

Skr2.16

Change (1 day)

-0.92%

52-Week Range

Skr1.84 - Skr2.56

All Time High

Skr2.56